Insmed (INSM) Non-Current Deffered Revenue (2012 - 2014)
Insmed (INSM) posted quarterly Non-Current Deffered Revenue of $118000.0 for Q4 2014, down 68.95% year-over-year from $380000.0 in Q4 2013, and down 36.22% quarter-over-quarter from $185000.0 in Q3 2014.
Insmed (INSM) Non-Current Deffered Revenue (2012 - 2014) Analysis & Trends
Insmed's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $118000.0 for Q4 2014.
- In Q4 2014, Non-Current Deffered Revenue fell 68.95% year-over-year to $118000.0; the TTM figure through Dec 2014 stood at $118000.0 (down 68.95% YoY), while the FY2014 annual figure was $118000.0, down 68.95% from the prior year.
- Non-Current Deffered Revenue for Q4 2014 stood at $118000.0, down from $185000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $647000.0 in Q4 2012, with the low at $118000.0 in Q4 2014.
- The 3-year median for Non-Current Deffered Revenue is $380000.0 (2013), against an average of $382000.0.
- The sharpest annual moves came in 2013 and 2014: Non-Current Deffered Revenue sank 41.27% in 2013, then slumped 68.95% in 2014.
- Insmed's Non-Current Deffered Revenue stood at $647000.0 in 2012, then tumbled by 41.27% to $380000.0 in 2013, then plunged by 68.95% to $118000.0 in 2014.
- Business Quant data shows INSM's Non-Current Deffered Revenue at $118000.0 in Q4 2014, $185000.0 in Q3 2014, and $250000.0 in Q2 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 118,000.00 |
| Sep 30, 2014 | 185,000.00 |
| Jun 30, 2014 | 250,000.00 |
| Mar 31, 2014 | 315,000.00 |
| Dec 31, 2013 | 380,000.00 |
| Sep 30, 2013 | 449,000.00 |
| Jun 30, 2013 | 514,000.00 |
| Mar 31, 2013 | 580,000.00 |
| Dec 31, 2012 | 647,000.00 |